Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified benzoxazinone derivatives acting as mineralocorticoid receptor (MR) antagonists reported to be useful for the treatment of diabetic nephropathy.